The Israel Innovation Authority, established in 1965 as the Office of the Chief Scientist within the Ministry of Industry and Trade, is dedicated to fostering research and development in government research institutes. Its primary objective is to enhance industrial development and promote the export of high-tech products. The authority plays a crucial role in mitigating financial risks associated with innovation projects by providing funding support to initiatives selected and managed by private companies. Through these efforts, it aims to stimulate growth in the high-tech sector and strengthen Israel's position as a leader in innovation.
Eretz Angels supports technology startups in Israel's outskirts at the start of their journey.
IR-MED
Grant in 2024
IR-MED Ltd. is a medical device company based in Rosh Pinna, Israel, specializing in infrared light-based diagnostic systems. Founded in 2012, the company utilizes advanced technologies such as big data and machine learning to enhance its diagnostic capabilities. IR-MED focuses on developing continuous and real-time monitoring systems that can detect and measure various substances and pharmaceuticals in the blood. Additionally, its technology allows for the assessment of fluid concentrations on surfaces and beneath thin tissues, facilitating the identification and characterization of diverse medical lesions and pathological processes in humans.
BloomX
Seed Round in 2023
BloomX is an AI pollination solution for crops in which pollination is a limiting factor for their yield. The company allows growers to increase their revenue by enlarging yields in existing crops and improving fruit quality. BloomX's vision is to provide an AI-based pollination solution that addresses each crop’s pollination needs by mimicking the natural pollination process and enhancing it using technology. Bumblebee was founded in 2019 and is headquartered in Tel Aviv, Israel.
BioBetter
Series A in 2022
BioBetter is a foodtech company founded in 2015 and based in Israel, specializing in the development of plant-based platforms for the production of complex growth factors essential for cultivated meat. The company focuses on leveraging the advantages of plants as bioreactors for protein expression by utilizing transgenic plants that co-express therapeutic proteins alongside enzymes that eliminate antigenic sugars. This innovative approach simplifies the manufacturing and purification of proteins and biological drugs, allowing biotech professionals to lower production costs effectively.
SuperMeat
Grant in 2022
SuperMeat is an Israeli biotech and food-tech company founded in 2015 and based in Tel Aviv. It specializes in producing cultured meat from chicken cells in a safe, controlled environment, eliminating the need for animal slaughter. This innovative approach to meat production aims to enhance nutritional security and reduce carbon emissions. By growing meat in a sterile setting, SuperMeat ensures that its products are free from antibiotics and the risk of fecal contamination, such as salmonella. The company emphasizes sustainability, as its clean meat production requires significantly fewer resources—99% less land and 90% less water—compared to traditional methods. SuperMeat aspires to transform the meat industry, offering a healthier and more sustainable food source for the future.
VALFIX
Grant in 2022
VALFIX Medical Ltd, established in 2016 and based in Tel Aviv, Israel, specializes in the design and development of transcatheter solutions for Mitral and Tricuspid valve repair and replacement. Their innovative, minimally-invasive approach combines repair and replacement treatments, providing a viable alternative to open-heart surgery. The company's multi-wire technology enables transcatheter mitral valve repair procedures, aiming to alleviate heart failure symptoms and treat various heart conditions by eliminating mitral regurgitation.
Enlivex Therapeutics
Grant in 2022
Enlivex Therapeutics Ltd. is a clinical-stage immunotherapy company headquartered in Nes Ziona, Israel, focused on developing allogeneic drugs aimed at rebalancing the immune system. The company's lead product, Allocetra, is an immunotherapy candidate currently undergoing multiple clinical trials. These include a Phase IIb trial for severe sepsis, an investigator-initiated Phase II trial for COVID-19 patients in severe and critical conditions, and a Phase IIa trial for preventing Graft Versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplants. Additionally, Enlivex is exploring Allocetra's potential in preventing complications from bone marrow transplants and acute multiple organ failure. The company also aims to develop cell-based therapies that enhance the efficacy of treatments for solid tumors through immune checkpoint rebalancing. Founded in 2005 by Professor Dror Mevorach, Enlivex utilizes a novel approach that focuses on inducing immune tolerance by employing apoptotic cells to modulate inflammatory and autoimmune responses.
BeeHero
Grant in 2021
BeeHero is a company that has developed an innovative beehive technology platform aimed at enhancing crop yields through effective pollination. Utilizing artificial intelligence and machine learning algorithms, the platform employs low-cost sensors to gather data from within beehives. This information helps stimulate optimal productivity during critical pollination periods, assisting farmers in safeguarding their beehives against colony collapse and improving overall pollination efficiency. Founded in 2017 by Itai Kanot, Omer Davidi, and Yuval Regev, BeeHero operates from locations in Tel Aviv and Silicon Valley, with a workforce of 50 employees, including 30 at its research and development center in Israel.
ViAqua Therapeutics
Grant in 2021
ViAqua Therapeutics Ltd is an Israeli company founded in 2014 that specializes in developing innovative drugs and therapeutics for the aquaculture industry. The company focuses on creating the first orally administered treatment designed to combat viral diseases affecting aquatic species, particularly shrimp. ViAqua's proprietary platform employs a unique RNAi nanoparticle formulation that triggers a cellular response to disable viral infections. This technology enables the delivery of coated nanoparticles through feed or immersion techniques, enhancing the resistance of aquaculture species against viral epidemics. With a management team experienced in business development and industrial biotechnology, ViAqua aims to improve the health and sustainability of aquaculture practices.
Enlivex Therapeutics
Grant in 2021
Enlivex Therapeutics Ltd. is a clinical-stage immunotherapy company headquartered in Nes Ziona, Israel, focused on developing allogeneic drugs aimed at rebalancing the immune system. The company's lead product, Allocetra, is an immunotherapy candidate currently undergoing multiple clinical trials. These include a Phase IIb trial for severe sepsis, an investigator-initiated Phase II trial for COVID-19 patients in severe and critical conditions, and a Phase IIa trial for preventing Graft Versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplants. Additionally, Enlivex is exploring Allocetra's potential in preventing complications from bone marrow transplants and acute multiple organ failure. The company also aims to develop cell-based therapies that enhance the efficacy of treatments for solid tumors through immune checkpoint rebalancing. Founded in 2005 by Professor Dror Mevorach, Enlivex utilizes a novel approach that focuses on inducing immune tolerance by employing apoptotic cells to modulate inflammatory and autoimmune responses.
FertilAI
Grant in 2021
FertilAI is a healthcare company focused on enhancing fertility treatment outcomes through advanced technology. The company has developed an AI-driven platform that streamlines the decision-making process for physicians, thereby improving the success rate of fertility treatments. Its algorithms are integrated into the Fertilane platform, which facilitates efficient communication among clinics, doctors, and patients via specialized applications designed for fertility workflows. Founded by a team of technology experts and leading reproductive endocrinologists in Israel, FertilAI aims to elevate the patient experience and enable clinics to scale their operations effectively.
Phytolon
Funding Round in 2020
Phytolon Ltd, founded in 2000 and based in Misgav, Israel, specializes in the development of natural food colorants. The company has established a novel and sustainable technology that utilizes fermentation processes with baker’s yeast cells as biofactories to produce high-quality, plant-based food colors. This innovative approach provides a healthy alternative to synthetic food dyes, offering food manufacturers safe, cost-effective, and stable all-natural colors. Phytolon is dedicated to promoting human health and environmental sustainability through scientific advancement in the food color industry.
Vessi Medical
Venture Round in 2020
Vessi Medical is an Israeli medical device startup focused on innovating treatment for Non-Muscle-Invasive Bladder Cancer (NMIBC) through a novel surface cryotherapy approach. This method employs extreme cold to freeze and eliminate abnormal tissue, addressing the limitations of traditional first-line therapies like TransUrethral Resection of Bladder Tumor (TURBT), which can be invasive, costly, and often result in cancer recurrence. Vessi's technology offers a minimally invasive, office-based therapy that reduces the need for hospital stays and repeat surgeries, which are common in conventional treatments. The system comprises a standalone console and a disposable catheter that allows for targeted cell destruction while safeguarding healthy bladder tissue. Vessi Medical, supported by the Trendlines Group and led by experienced professionals in the medical device and cryotherapy fields, has already shown promising results in animal studies. The company's initial focus is on the $1.2 billion NMIBC market, with plans to expand into treatment options for overactive bladder and urinary tract infections in the future.
Magentiq Eye
Non Equity Assistance in 2020
Magentiq Eye Ltd. is a medical device company based in Haifa, Israel, established in 2014. It specializes in developing advanced technologies for endoscopic procedures, particularly focusing on automatic polyp detection during colonoscopies. The company's flagship product, the Automatic Polyp Detection System (APDS), leverages deep learning and computer vision to enhance the accuracy of polyp identification, thereby reducing the miss rate during examinations. The APDS is available in two formats: APDS-RT, which operates in real-time by processing video feeds from endoscopic cameras, and APDS-OFL, which analyzes pre-recorded colonoscopy videos. Given the prevalence of colonoscopies—approximately 40 million performed annually—the system aims to improve patient outcomes by increasing detection rates and minimizing the risk of interval cancers. Magentiq Eye's technology not only supports physicians in making more informed decisions during procedures but also has the potential for integration with existing endoscopic equipment or as a service model for clinics and hospitals.
SafeUP - Women's Safety Net
Pre Seed Round in 2020
90 days from launch (Dec 20): - 4 paying clients in 90 days, 25 days sales cycle. - 10,000 users covering all 10 largest cities of Israel. Together with our SafeUPer we - Create a Safe World for Women - One community at a time. Create – We believe people must take an action, getting out of our comfort zone, to achieve this change. Sharing stories is simply not enough. Safe – We believe being safe is a basic right of all women, and like all women right achieved by previous generations, it will be gained with sweat and tears. World – We are facing a global problem, documented for at least two millennia (2,000 yrs), maybe the only problem impacting women daily, of all ages, countries, backgrounds and beliefs. Therefore. We believe it should be solved globally, empowering women all around the world to bring safety to their local communities. Women – We believe that when women will have peace, men too will have peace. Men have proven that they are unable to bring peace and safety by themselves to themselves nor to women. Therefore, we need to lead and bring it together.
DiA Imaging Analysis
Grant in 2020
DiA Imaging Analysis Ltd. specializes in AI-driven ultrasound analysis technology aimed at enhancing cardiac function diagnostics. Established in 2009 and based in Beersheba, Israel, the company provides a suite of automated tools, including LVivo EF for ejection fraction evaluation, LVivo RV for right ventricle analysis, and LVivo Strain for assessing myocardial strain. These solutions address common challenges faced by clinicians, such as obtaining optimal images and accurately analyzing them for clinical abnormalities. DiA's products, which can be integrated into any ultrasound device or healthcare IT system, also include LVivo SAX for detecting coronary heart disease and LVivo Mobile for mobile ultrasound analysis. The company holds regulatory clearances for its cardiac toolbox and serves a global user base, reflecting its commitment to making ultrasound analysis smarter and more accessible.
XRHealth
Grant in 2020
XRHealth Ltd. is a medical technology company based in Tel Aviv, Israel, that specializes in developing virtual reality (VR) software solutions for healthcare. Founded in 2016, the company offers an array of products designed to enhance patient care and treatment outcomes. Its offerings include VRPhysio, a platform for virtual physical therapy; VRReliever, which helps manage pain through distraction; VRCogni, aimed at improving motor function in stroke and dementia patients; and VRPsyc, which provides exposure therapy for various mental health disorders. Additionally, VRCoordi is designed to aid coordination recovery in patients with Parkinson's, brain injuries, and autism. By integrating immersive technologies with licensed clinicians and advanced data analytics, XRHealth provides comprehensive telehealth services, allowing patients to access treatment from the comfort of their own homes.
Enlivex Therapeutics
Grant in 2020
Enlivex Therapeutics Ltd. is a clinical-stage immunotherapy company headquartered in Nes Ziona, Israel, focused on developing allogeneic drugs aimed at rebalancing the immune system. The company's lead product, Allocetra, is an immunotherapy candidate currently undergoing multiple clinical trials. These include a Phase IIb trial for severe sepsis, an investigator-initiated Phase II trial for COVID-19 patients in severe and critical conditions, and a Phase IIa trial for preventing Graft Versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplants. Additionally, Enlivex is exploring Allocetra's potential in preventing complications from bone marrow transplants and acute multiple organ failure. The company also aims to develop cell-based therapies that enhance the efficacy of treatments for solid tumors through immune checkpoint rebalancing. Founded in 2005 by Professor Dror Mevorach, Enlivex utilizes a novel approach that focuses on inducing immune tolerance by employing apoptotic cells to modulate inflammatory and autoimmune responses.
AgroScout
Seed Round in 2020
AgroScout Ltd. is an Israeli company established in 2017 that specializes in developing an artificial intelligence-based platform aimed at enhancing sustainable farming practices. The company's technology provides precision agriculture solutions by utilizing advanced analytics and high-resolution aerial imagery to assess crop health and monitor for pests and diseases. AgroScout's platform supports farmers by offering insights on crop emergence, stand counts, canopy coverage, and biomass throughout the growing season. This continuous monitoring allows for early detection of infestations, enabling more effective curative treatments and reducing pesticide use. By delivering actionable insights into crop management and regional outbreak predictions, AgroScout aims to improve crop yields and profitability while fostering a more sustainable food production supply chain.
Indoor Robotics
Grant in 2020
Indoor Robotics Ltd, founded in 2018 and based in Ramat Gan, Israel, specializes in the design and development of Tando, an AI-powered patrol drone tailored for indoor security and inspection tasks. Tando employs independent AI-based navigation and a patented ceiling docking system, providing real-time coverage and utilizing predictive analysis to reduce false alarms. The drone autonomously collects and analyzes data, promoting consistent quality and enhancing safety. This innovative solution combines robotics with advanced AI capabilities, offering a cost-effective and efficient approach to intelligent indoor monitoring. By collaborating with leaders in the security and smart building sectors, Indoor Robotics aims to transform the landscape of indoor surveillance and inspection through improved area coverage and response times.
Yemoja
Seed Round in 2019
Yemoja Ltd. is a marine biotech company based in Upper Galilee, Israel, that specializes in the production of microalgae-derived products for various industries, including cosmetics, food, and pharmaceuticals. Established in 2017, Yemoja utilizes innovative and patented technology to manufacture high-quality ingredients such as astaxanthin, polysaccharides, xanthophylls, carotenoids, and enzymes. The company's product lineup includes solutions like DSkin, Algae Glow, and EPS Glow, which are derived from different species of microalgae. Yemoja is currently expanding its industrial capabilities by constructing a larger facility designed to meet Good Manufacturing Practices (GMP) standards, reinforcing its commitment to quality and sustainability in the production of bioactive and raw ingredients.
Greeneye Technology
Grant in 2019
Greeneye Technology is a company based in Tel-Aviv, Israel, founded in 2017, that focuses on precision agriculture through the use of artificial intelligence. The company has developed a proprietary selective spraying system that transforms conventional sprayers into smart machines capable of detecting weeds and applying herbicides precisely and in real-time. This innovative approach significantly reduces herbicide usage by as much as 90%, moving away from the traditional method of indiscriminate spraying. Greeneye's technology leverages machine learning and computer vision to automate field scouting and optimize herbicide application, providing farmers with valuable insights into their fields. The multidisciplinary team at Greeneye combines expertise in various fields, including agronomy and mechanical engineering, to deliver sustainable solutions that enhance agricultural practices globally.
Enlivex Therapeutics
Grant in 2019
Enlivex Therapeutics Ltd. is a clinical-stage immunotherapy company headquartered in Nes Ziona, Israel, focused on developing allogeneic drugs aimed at rebalancing the immune system. The company's lead product, Allocetra, is an immunotherapy candidate currently undergoing multiple clinical trials. These include a Phase IIb trial for severe sepsis, an investigator-initiated Phase II trial for COVID-19 patients in severe and critical conditions, and a Phase IIa trial for preventing Graft Versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplants. Additionally, Enlivex is exploring Allocetra's potential in preventing complications from bone marrow transplants and acute multiple organ failure. The company also aims to develop cell-based therapies that enhance the efficacy of treatments for solid tumors through immune checkpoint rebalancing. Founded in 2005 by Professor Dror Mevorach, Enlivex utilizes a novel approach that focuses on inducing immune tolerance by employing apoptotic cells to modulate inflammatory and autoimmune responses.
CathWorks
Grant in 2019
CathWorks Ltd. is a medical technology company that specializes in enhancing percutaneous coronary intervention (PCI) therapy decisions through its advanced computational science platform. Founded in 2013 and headquartered in Kfar-Saba, Israel, with an additional office in the United States, the company has developed the CathWorks FFRangio, a non-invasive device that provides objective, multi-vessel physiologic measurements. This tool transforms coronary angiography from a subjective visual assessment into an objective decision-making framework based on fractional flow reserve (FFR) metrics. By utilizing sophisticated algorithms to process visual information, CathWorks aims to improve the efficiency of cath lab operations and support healthcare providers in making data-driven clinical decisions.
RenalSense
Grant in 2019
RenalSense Ltd. is a medical device company based in Jerusalem, Israel, with an additional office in Brookline, Massachusetts. Founded in 2009, the company focuses on developing innovative solutions for real-time renal diagnostics to address the critical issue of acute kidney injury (AKI) in patients, particularly in intensive care settings. Its flagship product, Clarity RMS, is a monitoring system that continuously measures urine flow and automatically transmits real-time data to medical staff, allowing for early detection of changes in renal function. By providing timely alerts regarding fluctuations in urine flow, RenalSense aims to prevent the progression of kidney injury, which is often reliant on early detection. The company's technology seeks to establish new clinical standards, improve patient outcomes, and reduce healthcare costs associated with AKI management.
Soapy Care
Grant in 2019
Soapy Care Ltd, founded in 2017 and based in Tel Aviv, Israel, specializes in manufacturing IoT-powered hygiene micro-stations that ensure precise dosages of soap and water for handwashing. The company provides smart soap capsules that support regulatory compliance and enhance hygiene practices, addressing significant concerns about compliance, liability, and safety in various environments. Their innovative product turns handwashing into a digital experience, capturing valuable data that can benefit multiple stakeholders. Soapy Care has established a presence in the Indian market and is making its entry into the U.S., which is seen as a key market for expansion. The company has received numerous awards for its groundbreaking impact and operates with a strong team focused on reducing healthcare-associated infections and improving sanitation standards.
Ramino Bio
Seed Round in 2018
Ramino Bio is a private biotech company that develops an oral drug to treat metabolic diseases. Ramino has received funding totaling about $3.3 million since its beginning from the FutuRx biotech incubator, which is supported by the Israeli Innovation Authority, Takeda, J&J, OrbiMed, and RMPG. By speeding up their disintegration, our exclusive technology lowers the extra BCAA that is floating around.
Convizit
Grant in 2018
Convizit Ltd., based in Tel Aviv, Israel, specializes in web analytics software that utilizes AI technology to automatically capture and analyze user interactions on websites and SaaS applications. The platform collects detailed behavioral data with minimal effort required from users, eliminating the need for manual coding or tagging of events. By enriching this data with relevant properties, Convizit delivers a comprehensive stream of user behavior information directly to various analytics, marketing, and customer data platforms. This approach allows businesses to access reliable behavioral insights quickly, without the traditional challenges of data collection, which can be time-consuming and prone to inaccuracies. Convizit aims to transform the way organizations leverage behavioral data, enabling them to enhance analytics, business intelligence, and personalization efforts effortlessly. The company is actively expanding its team of developers and data scientists to further innovate within the digital analytics space.
DiA Imaging Analysis
Series A in 2018
DiA Imaging Analysis Ltd. specializes in AI-driven ultrasound analysis technology aimed at enhancing cardiac function diagnostics. Established in 2009 and based in Beersheba, Israel, the company provides a suite of automated tools, including LVivo EF for ejection fraction evaluation, LVivo RV for right ventricle analysis, and LVivo Strain for assessing myocardial strain. These solutions address common challenges faced by clinicians, such as obtaining optimal images and accurately analyzing them for clinical abnormalities. DiA's products, which can be integrated into any ultrasound device or healthcare IT system, also include LVivo SAX for detecting coronary heart disease and LVivo Mobile for mobile ultrasound analysis. The company holds regulatory clearances for its cardiac toolbox and serves a global user base, reflecting its commitment to making ultrasound analysis smarter and more accessible.
Magentiq Eye
Non Equity Assistance in 2018
Magentiq Eye Ltd. is a medical device company based in Haifa, Israel, established in 2014. It specializes in developing advanced technologies for endoscopic procedures, particularly focusing on automatic polyp detection during colonoscopies. The company's flagship product, the Automatic Polyp Detection System (APDS), leverages deep learning and computer vision to enhance the accuracy of polyp identification, thereby reducing the miss rate during examinations. The APDS is available in two formats: APDS-RT, which operates in real-time by processing video feeds from endoscopic cameras, and APDS-OFL, which analyzes pre-recorded colonoscopy videos. Given the prevalence of colonoscopies—approximately 40 million performed annually—the system aims to improve patient outcomes by increasing detection rates and minimizing the risk of interval cancers. Magentiq Eye's technology not only supports physicians in making more informed decisions during procedures but also has the potential for integration with existing endoscopic equipment or as a service model for clinics and hospitals.
MedAware
Grant in 2018
MedAware Ltd specializes in developing solutions aimed at detecting and eliminating prescription errors to enhance patient safety and reduce healthcare costs. Founded in 2012 and headquartered in Raanana, Israel, the company utilizes advanced data analytics and machine learning algorithms to analyze extensive electronic medical records. Its offerings include the MedAS alerting system for real-time alerts on prescription errors, MedRIM for risk management support, MedQC for quality control assistance, and MedRAF to reduce alert fatigue. These tools enable healthcare providers, pharmacy benefit management companies, and pharmacy chains to leverage big data effectively, identify potential prescription errors related to drug interactions, dosages, and allergies, and ultimately improve patient outcomes.
Phytolon
Pre Seed Round in 2018
Phytolon Ltd, founded in 2000 and based in Misgav, Israel, specializes in the development of natural food colorants. The company has established a novel and sustainable technology that utilizes fermentation processes with baker’s yeast cells as biofactories to produce high-quality, plant-based food colors. This innovative approach provides a healthy alternative to synthetic food dyes, offering food manufacturers safe, cost-effective, and stable all-natural colors. Phytolon is dedicated to promoting human health and environmental sustainability through scientific advancement in the food color industry.
Talenya
Grant in 2017
Talenya Ltd is a talent sourcing company that operates a technology-driven platform designed to identify and match suitable candidates with job opportunities. Founded in 2016 and based in Rosh Haayin, Israel, with an additional office in Hoboken, New Jersey, Talenya utilizes artificial intelligence and machine learning to gather and analyze data from various online sources. This enables the platform to assess and validate potential candidates, presenting only the most qualified individuals to employers. By automating the recruitment process, Talenya aims to streamline talent sourcing, saving time and increasing the efficiency of matching diverse talent with open positions.
SoftWheel
Grant in 2017
SoftWheel LTD. is a technology company based in Tel Aviv, Israel, specializing in the development of advanced in-wheel suspension technology for the wheelchair, bicycle, and automotive sectors. Founded in 2011, the company designs innovative suspension systems that absorb shocks and vibrations, enhancing comfort and performance for users, particularly in wheelchairs. SoftWheel's products also contribute to improvements in energy efficiency and overall mobility. The company markets its suspension arms and wheel rims through a network of resellers both in Israel and internationally. To strengthen its position in the market, SoftWheel has established strategic partnerships with notable global firms, including NSK and Linamar.
Yarok Microbio
Grant in 2017
Yarok Microbio has developed an innovative microbiological testing technology that significantly enhances the speed and accuracy of pathogen detection in the food supply chain and agriculture. The system can identify dangerous microbes such as E. coli, Listeria, Salmonella, and various yeasts and molds within 45 minutes, a substantial improvement over traditional testing methods that take days. This rapid testing capability helps food producers safeguard consumer health, prevent costly product recalls, and mitigate potential legal issues. Additionally, Yarok's technology allows for early detection of plant pathogens, enabling agricultural producers to implement timely phytosanitary measures and reduce pesticide use, thereby minimizing losses of high-value crops. The company's research and development laboratory is located in Jerusalem, Israel, while a demonstration lab in Milan, Italy, supports marketing efforts in Europe. Yarok has been recognized for its contributions to agribusiness innovation, receiving the 2017 Innovation Award from the United Nations Industrial Development Organization and being named one of the top disruptors in the food technology sector by the Institute of Food Technologists in 2019.
ElastiMed
Venture Round in 2017
ElastiMed Ltd. specializes in the development of innovative medical devices focused on compression therapy, specifically for treating Chronic Venous Insufficiency and preventing Deep Venous Thrombosis. Founded in 2015 and headquartered in Misgav, Israel, the company has created a wearable active compression device that employs advanced smart materials. This device, often referred to as a smart sock, uses electric pulses to compress and massage the legs, enhancing circulation and offering a comfortable and effective treatment solution. It aims to provide an affordable option for patients, particularly the elderly, to alleviate symptoms such as swelling, blood clots, leg ulcers, and sports injuries, thereby improving their overall quality of life.
Augmedics
Series A in 2017
Augmedics Ltd. is a company that specializes in augmented reality surgical guidance systems, aiming to enhance the safety and effectiveness of surgical procedures. Founded in 2014 and headquartered in Yoqneam Ilit, Israel, with an additional office in Chicago, Illinois, the company has developed the xvision-spine (XVS) system. This innovative system features a head-mounted display that allows surgeons to visualize a patient's anatomy through skin and tissue, providing real-time insights into the position of surgical tools and illuminating the surgical area. By integrating advanced technologies, Augmedics seeks to transform surgical treatment and improve patient outcomes during complex operations.
Gamida Cell
Grant in 2017
Gamida Cell is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for patients with blood cancers and serious hematologic diseases. The company's lead product candidate, omidubicel, is an advanced therapy utilizing nicotinamide-expanded hematopoietic stem cells, currently undergoing Phase 3 trials for patients with high-risk hematologic malignancies and a Phase 1/2 trial for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based immunotherapy that is in Phase 1/2 studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998 and headquartered in Jerusalem, Israel, the company employs a proprietary expansion platform that enhances the properties of nicotinamide to optimize allogeneic cell sources, including umbilical cord blood-derived cells.
AbiliSense
Grant in 2017
AbiliSense Ltd, founded in 2015 and based in Tel Aviv-Yafo, Israel, specializes in sound recognition technology designed to assist individuals with hearing impairments. The company has developed an AI-driven system that enhances Internet of Things (IoT) devices with smart listening capabilities. This technology continuously monitors environmental sounds and can alert users to critical information such as danger, accidents, anomalies, and suspicious activities. Alerts are sent directly to applications, emergency call centers, or various smart devices, ensuring real-time communication of important events. AbiliSense's innovative approach aims to transform auditory signals into actionable insights, thereby improving safety and awareness for those with hearing challenges.
Gamida Cell
Grant in 2016
Gamida Cell is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for patients with blood cancers and serious hematologic diseases. The company's lead product candidate, omidubicel, is an advanced therapy utilizing nicotinamide-expanded hematopoietic stem cells, currently undergoing Phase 3 trials for patients with high-risk hematologic malignancies and a Phase 1/2 trial for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based immunotherapy that is in Phase 1/2 studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998 and headquartered in Jerusalem, Israel, the company employs a proprietary expansion platform that enhances the properties of nicotinamide to optimize allogeneic cell sources, including umbilical cord blood-derived cells.
Nanofabrica
Grant in 2016
Nanofabrica, founded in 2016 and based in Tel Aviv, Israel, specializes in advanced 3D printing technology for precision manufacturing. The company focuses on micro and nanomanufacturing, providing solutions for sectors such as robotics, semiconductors, optics, and medical devices. Its innovative Micro Adaptive Projection technology allows for the production of ultra-precise parts with micron-resolution, enabling the creation of complex designs at competitive prices. By integrating semiconductor lithography and advanced optics within its 3D printing processes, Nanofabrica offers a unique capability to meet the demands of mass customization and rapid production. The company actively seeks customer feedback to refine its technology and tackle new challenges, positioning itself as a leader in the evolving landscape of additive manufacturing.
Atomation
Seed Round in 2015
Atomation is a company that specializes in developing an Internet of Things (IoT) platform designed to connect existing legacy objects and assets to the internet. Founded in 2014 and headquartered in Saint Louis, Missouri, with origins in Tel Aviv, Israel, Atomation focuses on transforming data gathered from sensors into actionable insights. Its platform supports various sectors, including agriculture, medical, industrial, and logistics, by enabling devices to interact, analyze information, and make real-time decisions. Atomation offers both software and hardware development kits, providing businesses with affordable and straightforward solutions to enhance their operations and optimize their performance.
Catalyst AgTech
Seed Round in 2015
Catalyst AgTech Ltd. is an innovative Israeli company focused on developing advanced technology for the agricultural sector. The company specializes in creating customizable catalysts that enhance the effectiveness of agrochemicals, such as pesticides, herbicides, and fungicides, while minimizing their environmental impact. Its patented technology features a self-destruction mechanism that ensures these chemicals break down after their intended use, significantly reducing the risk of groundwater contamination. By addressing the pressing issue of agrochemical pollution, Catalyst AgTech aims to reconcile the increasing demand for effective pest control with the necessity of environmental protection. Backed by scientific expertise from the Weizmann Institute of Science and supported by Trendlines Agtech – Mofet as a partner and investor, the company is positioned to contribute meaningfully to sustainable agriculture and drive significant business growth.
IR-MED
IR-MED Ltd. is a medical device company based in Rosh Pinna, Israel, specializing in infrared light-based diagnostic systems. Founded in 2012, the company utilizes advanced technologies such as big data and machine learning to enhance its diagnostic capabilities. IR-MED focuses on developing continuous and real-time monitoring systems that can detect and measure various substances and pharmaceuticals in the blood. Additionally, its technology allows for the assessment of fluid concentrations on surfaces and beneath thin tissues, facilitating the identification and characterization of diverse medical lesions and pathological processes in humans.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.